TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Benzinga Logo Benzinga • •By Vandana Singh
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Pfizer's Phase 3 study reveals a new nucleoside-modified mRNA influenza vaccine with 34.5% relative efficacy against flu strains, showing superior protection compared to traditional vaccines, though with higher short-term side effects.

Insights
PFE   positive

Demonstrated superior vaccine efficacy in clinical trials, showing potential breakthrough in flu prevention technology